Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases

Inclusion Criteria: Patients must meet all of the following criteria to be eligible for enrollment into the study: 1. Age ≥ 18 years. 2. Histologically or cytologically metastatic NSCLC (UICC/AJCC TNM Staging System, 9th Edition, Stage Ⅳ). 3. At least one measurable target tumor lesion as accessed by RECIST v1.1 criteria. 4. Radiographically confirmed brain metastasis(es) , with stable CNS symptoms within 2 weeks prior to enrollment. 5. Documented ROS1 gene fusion identified by an approved molecular testing method (FISH, RT-PCR, or NGS). 6. Considered by the investigator to be candidates for Taletrectinib treatment ; OR Patients with ≤6 months of prior Taletrectinib exposure enrolled retrospectively. (Note: For retrospective patients deceased before enrollment, waiver of informed consent is required. Patients who initiated and discontinued treatment within 6 months prior to signing informed consent are eligible). 7. Signed Informed Consent. Exclusion Criteria: Patient presenting with any of the following criteria will not be included in the study： 1. Patients with driver gene mutations/alterations that have approved targeted therapies , including but not limited to EGFR, ALK, RET, etc. 2. Currently participating in other interventional clinical trials or having received investigational drug treatment within 4 weeks prior to enrollment . 3. Pregnancy or breastfeeding. 4. Patients with uncontrolled co-morbidities who are assessed by the investigator not to receive targeted therapy. 5. Other conditions that are assessed by the investigator to be unsuitable for enrollment in this study.